SCHEMBL6497121

SCHEMBL6497121

CC(C)(C)OC(=O)N1CCC(c2cc3[nH]c(=S)[nH]c3cc2Cl)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.50
KDM4E B2RXH2 1/20 0.50
THRB P10828 1/20 0.50
STS P08842 5/20 0.43
CNR1 P21554 1/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
HTT P42858 2/20 0.41
USP2 O75604 1/20 0.41
HPGD P15428 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HSD17B10 Q99714 1/20 0.41
TOP2A P11388 1/20 0.41
GPR119 Q8TDV5 2/20 0.40
HPGDS O60760 1/20 0.40
NPC1 O15118 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPK1 P28482 1/20 0.40
RAB9A P51151 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6484073 0.80 MAPT (0.55) MAPTKDM4ETHRBSTSMEN1
SCHEMBL20424278 0.79 KDM4E (0.47) MAPTKDM4ETHRBCNR1MEN1
SCHEMBL23291499 0.78 STS (0.50) MAPTKDM4ETHRBSTSCNR1
SCHEMBL22438213 0.77 TLR8 (0.45) MAPTKDM4ETHRBSTSCNR1
SCHEMBL4786221 0.77 CNR1 (0.56) MAPTKDM4ETHRBSTSCNR1
SCHEMBL22438925 0.77 MAPT (0.45) MAPTKDM4ETHRBSTSCNR1
SCHEMBL6485162 0.76 MAPT (0.51) MAPTKDM4ESTSMEN1KMT2A
SCHEMBL17398495 0.76 ESR2 (0.52) MAPTKDM4ETHRBSTSCNR1
SCHEMBL14325302 0.76 KDM4E (0.51) MAPTKDM4ETHRBSTSCNR1
SCHEMBL19702760 0.76 MAPT (0.53) MAPTKDM4ETHRBSTSMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6969712-B2 Benzimidazole derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2005-11-29 US disclosed
US-20040044056-A1 Benzimidazole derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2004-03-04 US disclosed
EP-1342717-A1 BENZIMIDAZOLE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2003-09-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040044056-A1 Benzimidazole derivatives GPR119, OPRL1, INSR MAPT 400/4885KDM4E 2367/4885THRB 243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.